Astellas, Aveo End Collaboration On Developing Tivozanib As Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and U.S.-based Aveo Oncology are dropping their collaboration on developing tivozanib as a treatment for breast and colon cancers because of poor results in a Phase II trial.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.